CTNNB1 and neoplasm: To better understand the molecular drivers of the tumor's aggressive and hyperandrogenic phenotype, we performed whole-exome sequencing, which uncovered 2 rare somatic mutations—BCOR P1384R and HDAC9 R947P—in the absence of TP53 or CTNNB1 alterations.